A randomized phase 2 study comparing EC or CMF versus nab-paclitaxel plus capecitabine as adjuvant chemotherapy for nonfrail elderly patients with moderate to high-risk early breast cancer (ICE II-GBG 52) - Minckwitz, Gunter von; Conrad, Bettina; Reimer, Toralf; Decker, Thomas; Eidtmann, Holger; Eiermann, Wolfgang; Hackmann, John; Möbus, Volker; Marmé, Frederik; Potenberg, Jochem; Stickeler, Elmar; Simon, Eike; et al. (Cancer, 2015)